24 October 2016
: Case report
High-Dose Intravenous Vitamin C Treatment of a Child with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Case Report
Unusual clinical course, Unusual or unexpected effect of treatment, Unexpected drug reaction
Nina MikirovaABCDEF, Ronald HunnunghakeD, Ruth C. ScimecaBCDEF, Charles ChinshawDE, Faryal AliD, Chris BrannonB, Neil RiordanDGDOI: 10.12659/AJCR.899754
Am J Case Rep 2016; 17:774-781
Abstract
BACKGROUND: In neurofibromatosis type 1 (NF1) disease, the loss of the tumor suppressor function of the neurofibromin gene leads to proliferation of neural tumors. In children, the most frequently identified tumor is the optic pathway glioma.
CASE REPORT: We describe the case of a 5-year-old child who was diagnosed with NF1 and optic pathway tumor onset at the age of 14 months. Because of the tumor progression, chemotherapy with carboplatin and vincristine was prescribed at this early age and continued for one year. As the progression of disease continued after chemotherapy, the child, at the age of 2.8 years, was started on high-dose intravenous vitamin C (IVC) treatment (7–15 grams per week) for 30 months. After 30 months, the results of IVC treatments demonstrated reduction and stabilization of the tumors in the optic chiasm, hypothalamus, and left optic nerve according to radiographic imaging. The right-sided optic nerve mass seen before IVC treatment disappeared by the end of the treatment.
CONCLUSIONS: This case highlights the positive effects of treating NF1 glioma with IVC. Additional studies are necessary to evaluate the role of high-dose IVC in glioma treatment.
Keywords: Ascorbic Acid, Neurofibromatosis 1, Optic Nerve Glioma
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947185
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946911
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947730
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946625
Most Viewed Current Articles
21 Jun 2024 : Case report
98,573
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
52,979
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
33,819
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report
23,921
DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200